Acura Pharmaceuticals


Roth Capital Affirms Buy On Acura Pharmaceuticals Following NIDA Grant

In a research note issued yesterday to investors, Roth Capital analyst Ed Arce affirmed a Buy rating on Acura Pharmaceuticals (ACUR) with a $1.50 price target, after …

Roth Capital Maintains Buy On Acura But Reduces PT To $1.50 Following FDA Meeting Outcome

Acura Pharmaceuticals (ACUR) announced preliminary outcomes from its August 14 meeting with the FDA in which the Agency requests an additional nasal abuse liability study …

Roth Capital Reaffirms Buy On Acura Pharmaceuticals Following 2Q14 Results; Sees Partnership Opportunity

In a research note published yesterday, Roth Capital analyst Ed Arce reaffirmed a Buy rating on Acura Pharmaceuticals (ACUR) with a $2.50 price …